BFKW

Name

BFKW

Legal name

BFKW, LLC

Website

https://bfkw.org

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

1–10 employees

Short description

BFKW, LLC is a small Michigan-based medical-device developer of the Full Sense™ Device, a temporary implantable satiety-inducing weight-loss product. It is privately held, founded in 2004, and reliant on periodic securities offerings rather than disclosed commercial revenue.

Ownership category

akta.pro rank

Headquarters

HQ city

Grand Rapids

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Operations

Revenue model

1. Securities offering: The company conducts securities offerings including equity and pooled investment fund interests, with up to $12 million in securities available and $1.83 million already sold. The offering is scheduled to last more than one year.

Core offering

BFKW develops and manufactures the Full Sense™ Device, a temporary implantable medical device designed to induce long-lasting satiety and produce significant weight loss in patients. The company is a small, privately held medical device firm based in Grand Rapids, Michigan, focused on bariatric treatment solutions for obesity.

Differentiator

Problem solved

Functional benefit

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators1 record

Direct peers

• Spatz FGIA: Spatz Medical makes the Spatz3 adjustable gastric balloon, an endoscopic temporary implant for weight loss. It is a direct peer in the temporary, endoscopically-delivered satiety/space-occupying obesity device category.
• Obalon Therapeutics: Obalon developed a swallowable, gas-filled intragastric balloon system for weight loss. It is a direct peer competing for the minimally-invasive, temporary obesity device niche that BFKW's Full Sense Device also targets.
• Allurion Technologies: Allurion develops a swallowable, procedureless gastric balloon for weight loss. It is the closest direct peer to BFKW, competing for the same non-permanent, minimally-invasive obesity device niche that targets patients seeking alternatives to bariatric surgery.
• Aspire Bariatrics (AspireAssist): Aspire Bariatrics developed the AspireAssist, an endoscopically-implanted weight loss device. It is a direct peer in the category of temporary, endoscopically-delivered obesity intervention devices.
• Reshape Lifesciences (formerly ReShape Lifesciences, now part of Biorad): Reshape Lifesciences markets the Lap-Band adjustable gastric banding system for surgical weight loss. It is a direct competitor in the implantable obesity device space, though its product is permanent rather than temporary like BFKW's Full Sense Device.

Broad incumbents

• Johnson & Johnson (Ethicon): Through Ethicon, J&J is a broad incumbent in bariatric/metabolic surgical devices. While it does not offer a temporary satiety implant, it represents the established surgical obesity device market that BFKW would need to disrupt or partner with for commercial reach.
• Medtronic: Medtronic is a broad incumbent in surgical and metabolic devices, including bariatric surgery tools. It is comparable as a potential strategic acquirer or distribution partner for BFKW's endoscopic implant category.
• Apollo Endosurgery: Apollo Endosurgery (acquired by Boston Scientific) commercializes endoscopic obesity devices including the Orbera intragastric balloon. It competes in the same endoscopic obesity intervention category and was the broad incumbent leader before its acquisition.

Others

• Novo Nordisk: Novo Nordisk markets Wegovy (semaglutide), the leading GLP-1 obesity drug. It is adjacent rather than directly competitive, but defines the pharmaceutical standard-of-care against which any obesity device (including BFKW's Full Sense Device) must compete for share of voice and reimbursement.
• Eli Lilly: Eli Lilly markets Zepbound (tirzepatide) for obesity. Like Novo Nordisk, it is an adjacent rather than direct competitor, but its rapid commercial success in the obesity space sets the competitive baseline for weight loss efficacy expectations that BFKW's implant must meet or exceed.

Market position

Customer concentration

• LinkedInlinkedin.com/company/bfkw-llc

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds3 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BFKW